Drugs Xagena
The FDA ( Food and Drug Administration ) has approved Everolimus tablets ( Afinitor ) for the treatment of patients with advanced renal cell carcinoma after failure of treatment with Sunitinib or Sora ...
The FDA ( Food and Drug Administration ) has approved Zortress ( Everolimus ) oral tablets for the prevention of organ rejection of kidney transplants in adult patients at low-to-moderate immunologic ...
Votubia is a medicine that contains the active substance Everolimus. It is available as tablets ( 2.5, 5, 10 mg ). Votubia is used to treat the following benign tumours caused by the genetic disease t ...
The Chemotherapy Clinical Reference Group ( CRG ) has reviewed drugs and drug indications for inclusion on the National cancer drugs fund list. The decision summaries record how each drug/drug indica ...
Study 205 is a multicenter, randomized, open-label study of Lenvatinib ( 18 mg ) in combination with the anticancer agent Everolimus ( 5 mg ), Lenvatinib alone ( 24 mg ), and Everolimus alone ( 10 mg ...
The FDA ( Food and Drug Administration ) has approved Opdivo ( Nivolumab ) to treat patients with advanced ( metastatic ) renal cell carcinoma, who have received a certain type of prior therapy. Op ...
The U.S. Food and Drug Administration ( FDA ) has approved an additional indication for Lenvima ( Lenvatinib mesylate ) in combination with Everolimus ( Afinitor ) for the treatment of patients with a ...
The FDA ( Food and Drug Administration ) has approved Cabometyx ( Cabozantinib ) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy. The ...
The Committee for Medicinal Products for Human Use ( CHMP ), the scientific committee of the European Medicines Agency ( EMA ) has provided a positive opinion for Cabometyx ( Cabozantinib ) 20, 40, 6 ...
The European Commission ( EC ) has issued a marketing authorisation for Kisplyx ( Lenvatinib ) in combination with Everolimus ( Afinitor ) for the treatment of adult patients with advanced renal cell ...
